Medicinal mushrooms and type 2 diabetes: mechanistic insights, translational evidence, and clinical caveats

Abstract

Type 2 diabetes mellitus (T2DM) is a highly prevalent and rapidly expanding global metabolic disorder. Medicinal mushrooms have recently been proposed as promising functional foods, owing to their broad range of bioactive compounds, including β-glucans and other polysaccharides, triterpenoids, phenolic metabolites, sterols, nucleoside analogs, and sulfur-containing antioxidants. Their bioactivity is increasingly understood as an emergent property of multi-scale interactions, in which structural glycan complexity, supramolecular organization, and chemically diverse low-molecular-weight metabolites act in a network-like fashion rather than through single-target mechanisms. This review provides an integrated synthesis of the antidiabetic potential of medicinal mushrooms, encompassing ethnopharmacological origins, chemical diversity, preclinical and clinical evidence, and mechanistic pathways. Preclinical studies consistently report improvements in glucose homeostasis, insulin sensitivity, lipid metabolism, and redox balance across diverse experimental models. These effects are associated with modulation of insulin–PI3K/Akt and AMPK signaling, Nrf2-dependent antioxidant responses, NF-κB–driven inflammatory pathways, and gut microbiota–host metabolic interactions involving short-chain fatty acids and incretin signaling. However, most mechanistic evidence remains pathway-associated rather than causally validated, and the clinical relevance of many findings is limited by uncertain dose–response relationships, sparse pharmacokinetic data, preparation heterogeneity, and incomplete safety evaluation. Mushroom–drug interactions, liver safety, and environmental contaminant screening of concentrated mushroom-derived products warrant particular attention. Together, these factors constrain clinical translation, further compounded by heterogeneity of interventions, lack of standardization, short trial durations, and limited integration of mechanistic endpoints. Overall, medicinal mushrooms show potential as multi-target functional foods capable of modulating core pathological networks in T2DM. Future progress will critically depend on rigorous standardization of bioactive preparations, mechanistically driven clinical trials, and systems-level multi-omics integration to establish causal links between fungal bioactives and metabolic outcomes.